Free Trial
→ Elon’s Biggest Launch Ever: 15x Bigger Than SpaceX (From InvestorPlace) (Ad)tc pixel
NASDAQ:NRXS

NeurAxis 5/27/2026 Earnings Report

NeurAxis logo
$8.60 -0.20 (-2.22%)
As of 12:36 PM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileForecast

NeurAxis EPS Results

Actual EPS
N/A
Consensus EPS
-$0.19
Beat/Miss
N/A
One Year Ago EPS
N/A

NeurAxis Revenue Results

Actual Revenue
N/A
Expected Revenue
$1.45 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

NeurAxis Announcement Details

Quarter
Date
5/27/2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

NeurAxis Earnings Headlines

This Small-Cap Healthcare Stock Is Up 300% in a Year and Is Quickly Gaining a Following
May 6 at 11:22 PM  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/small-cap-healthcare-stock-300-154003142.html
NeurAxis to Host First Quarter 2026 Results and Business Update Call on Tuesday, May 12, 2026
May 5 at 7:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/05/3287475/0/en/neuraxis-to-host-first-quarter-2026-results-and-business-update-call-on-tuesday-may-12-2026.html
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.tc pixel
May 8 at 1:00 AM  |  Profits Run (Ad)
NeurAxis (NRXS) price target increased by 29.41% to 11.22
April 28, 2026  |  msn.comhttps://www.msn.com/en-us/money/topstocks/neuraxis-nrxs-price-target-increased-by-2941-to-1122/ar-AA21UIgT
Neuraxis, Inc. Common Stock (NRXS)
April 25, 2026  |  nasdaq.comhttps://www.nasdaq.com/market-activity/stocks/nrxs/pre-market
NeurAxis Expands At-The-Market Equity Offering Capacity
April 22, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/neuraxis-expands-at-the-market-equity-offering-capacity?utm_source=marketbeat.com&utm_medium=referral
See More NeurAxis Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like NeurAxis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NeurAxis and other key companies, straight to your email.

About NeurAxis

NeurAxis (NASDAQ:NRXS) (NASDAQ: NRXS) is a clinical-stage biotechnology company focused on the discovery and development of therapeutic candidates for diseases of the central nervous system. The company leverages a proprietary approach to deliver small molecules and biologics across the blood–brain barrier, aiming to address conditions ranging from acute neural injury to chronic neurodegenerative disorders.

NeurAxis advances its pipeline through a combination of in-house research, external collaborations with academic medical centers and contract research organizations, and strategic licensing agreements. Its lead programs are designed to modulate key pathways involved in neuronal survival and regeneration, with preclinical and early-stage clinical studies underway to assess safety, pharmacokinetics and proof of concept.

Headquartered in the United States, NeurAxis engages with international partners to support its translational and clinical development activities. The company’s common shares trade on the Nasdaq Stock Market under the ticker symbol NRXS.

View NeurAxis Profile
Earnings Tools